CheckMate 650 was a multicohort phase 2 trial designed to study the safety and clinical activity of nivolumab plus ipilimumab combination therapy in patients with metastatic castration-resistant prostate cancer. Here the authors report the results of the randomized portion of the trial, including three different immunotherapy treatment cohorts and a current standard-of-care chemotherapy cohort (cabazitaxel).
- Padmanee Sharma
- Michael Krainer
- Russell K. Pachynski
